Skip to content
Injectable Index

Sculptra

Sculptra is a poly-L-lactic acid (PLLA) implant supplied as a sterile dry powder that is reconstituted before injection. Its identity includes more than the 150 mg of PLLA in each vial: sodium carboxymethylcellulose (CMC), mannitol, preparation instructions, approved-use language, and market-specific labeling all shape how the product is handled and interpreted.

Quick reference

Section titled “Quick reference”
FieldSculptra
MaterialPoly-L-lactic acid microparticles
Dry-vial composition150 mg PLLA, 90 mg sodium CMC, 127.5 mg non-pyrogenic mannitol
PresentationSterile dry powder in a single-use vial
PreparationReconstituted with sterile water for injection; exact instructions depend on the current market-specific IFU
Immediate correctionEarly fluid-related fullness is not the final tissue response
Company contextGalderma brand and commercial portfolio; Q-Med AB appears as the FDA applicant
Main comparisonLanluma shares PLLA but not an assumed protocol

The composition and preparation fields above come from Galderma’s current global Sculptra IFU, version 4.7 (Galderma IFU 🔗).

Formulation and physical form

Section titled “Formulation and physical form”

The IFU describes Sculptra as a sterile, non-pyrogenic suspension formed by reconstituting a dry powder. The suspension contains crystalline PLLA microparticles. CMC and mannitol are part of the product’s dry-vial formulation rather than optional additions.

This physical form distinguishes Sculptra from:

  • prefilled HA gels
  • CaHA microspheres supplied in a ready-to-use gel carrier
  • hybrid PDLLA + HA products
  • ready-to-use PCL microsphere implants
  • manufacturer-described solubilized PCL systems

The presence of CMC should not lead to the conclusion that Sculptra behaves like a CMC carrier-gel filler. The reconstituted fluid and the PLLA-related delayed response need to be interpreted as different phases.

Presentation and preparation

Section titled “Presentation and preparation”

Galderma’s global IFU version 4.7 states that the dry powder is reconstituted with 5–8 mL of sterile water for injection. It permits an optional additional 1 mL of sterile 2% lidocaine, producing a final volume of 6–9 mL.

These figures belong to that specific IFU. They should not be presented as:

  • the only historically used Sculptra preparation
  • a rule for every regional label
  • an instruction for another PLLA brand
  • evidence that every final volume produces the same clinical behavior

The same IFU describes product-specific placement and treatment guidance. Those details should be read directly before clinical use rather than reconstructed from an index page.

Intended use and approval context

Section titled “Intended use and approval context”

The global IFU describes use for increasing the volume of depressed facial areas, including creases, wrinkles, folds, skin aging, and larger-volume correction of facial lipoatrophy.

US approval history is narrower and has changed through supplements. The FDA’s 2009 Sculptra Aesthetic approval concerned immune-competent people and correction of nasolabial-fold contour deficiencies and other facial wrinkles for which the labeled deep-dermal technique was appropriate (FDA PMA supplement 🔗). Later FDA records include cheek-wrinkle evidence and additional labeling changes (FDA labeling document 🔗; FDA PMA history 🔗).

Do not turn an international intended-use statement, a US approval, a clinical paper, and common injector practice into one universal list of approved areas.

Immediate appearance and delayed response

Section titled “Immediate appearance and delayed response”

Immediately after treatment, injected fluid can make a depression look corrected. That early appearance changes as the water is absorbed. The intended longer-term change develops gradually and is discussed in relation to the tissue response around PLLA.

This sequence affects:

  • consultation language
  • the timing of reassessment
  • decisions about additional correction
  • photography and outcome reporting
  • interpretation of early “loss of result”

The global IFU advises reassessment no sooner than four weeks after the first treatment when deciding whether additional correction is needed. This is product guidance, not a universal PLLA rule.

Company and regulatory roles

Section titled “Company and regulatory roles”
RoleSupported relationship
Brand and commercial portfolioGalderma
FDA applicant in current PMA recordsQ-Med AB
Product-specific legal manufacturerVerify from the exact regional label or IFU
Local approval holder or distributorMarket-specific

Galderma’s product page identifies Sculptra as a core aesthetic product and states that it is available across multiple countries (Galderma Sculptra 🔗). FDA records should be used for US approval facts, not to infer commercial or approval-holder roles elsewhere.

The Galderma company page places Sculptra within the wider corporate and regulatory graph.

Safety and limitations

Section titled “Safety and limitations”

The product’s warnings and contraindications should be taken from the current local labeling. Practitioner interpretation should distinguish:

  • expected injection-site swelling, tenderness, bruising, or redness
  • early palpable product or edema
  • non-inflammatory papules or nodules
  • inflammatory nodules
  • infection
  • delayed granulomatous reaction
  • vascular events

Product preparation, depth, distribution, anatomy, patient factors, and follow-up may all matter, but no single handling change guarantees absence of nodules or other complications.

Sculptra is not an HA-only filler and does not have a simple product-wide enzymatic dissolution pathway analogous to hyaluronidase treatment of many HA gels.

Nearby reference pages

Section titled “Nearby reference pages”